Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
Lukas John(University of Hohenheim), Nicola Giesen(German Cancer Research Center), Carsten Müller‐Tidow(Heidelberg University), Axel Benner(Memorial Sloan Kettering Cancer Center), Hartmut Goldschmidt(Heidelberg University), Karin Jordan(Heidelberg University), Marc S. Raab(Unknown), Michael Hundemer(Heidelberg University), Kaya Miah(German Cancer Research Center), Dorothee Kaudewitz(Innsbruck Medical University), Katharina Kriegsmann(Getrag (Germany))
Cited by 5
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493